{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:55:18Z","timestamp":1780646118398,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13181-021-00873-0","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:02:41Z","timestamp":1647878561000},"page":"187-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure"],"prefix":"10.1007","volume":"18","author":[{"given":"Michael D.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Raulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith W.","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Coley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna W.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Raine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Horwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek L.","family":"Eisnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Wolling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keli","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Jepson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"6","key":"873_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1553-2712.1998.tb02471.x","volume":"5","author":"T Okumura","year":"1998","unstructured":"Okumura T, Suzuki K, Fukuda A, Kohama A, Takasu N, Ishimatsu S, Hinohara S. The Tokyo subway sarin attack: disaster management, part 2: hospital response. Acad Emerg Med. 1998;5(6):618\u201324. https:\/\/doi.org\/10.1111\/j.1553-2712.1998.tb02471.x.","journal-title":"Acad Emerg Med"},{"key":"873_CR2","unstructured":"U.N. Mission to investigate allegations of the use of chemical weapons in the Syrian Arab Republic: report on the alleged use of chemical weapons in the Ghouta Area of Damascus on 21 August 2013. United Nations. 13 September 2013. https:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/Secretary_General_Report_of_CW_Investigation.pdf . Accessed 22 May 2021."},{"key":"873_CR3","unstructured":"Doctors Without Borders. Thousands suffering neurotoxic symptoms treated in hospitals supported by MSF. https:\/\/www.msf.org\/syria-thousands-suffering-neurotoxic-symptoms-treated-hospitals-supported-msf . Accessed 22 May 2021."},{"issue":"4","key":"873_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1067\/mem.2003.103","volume":"41","author":"RJ Geller","year":"2003","unstructured":"Geller RJ, Lopez GP, Cutler S, Lin D, Bachman GF, Gorman SE. Atropine availability as an antidote for nerve agent casualties: validated rapid reformulation of high-concentration atropine from bulk powder. Ann Emerg Med. 2003;41(4):453\u20136. https:\/\/doi.org\/10.1067\/mem.2003.103.","journal-title":"Ann Emerg Med"},{"key":"873_CR5","doi-asserted-by":"publisher","unstructured":"Schwartz MD, Sutter ME, Eisnor D, Kirk MA. Contingency medical countermeasures for mass nerve-agent exposure: use of pharmaceutical alternatives to community stockpiled antidotes. Disaster Med Public Health Prep. 2018;1\u20138. https:\/\/doi.org\/10.1017\/dmp.2018.99.","DOI":"10.1017\/dmp.2018.99"},{"issue":"3","key":"873_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13181-018-0658-4","volume":"14","author":"A Stolbach","year":"2018","unstructured":"Stolbach A, Bebarta V, Beuhler M, Carstairs S, Nelson L, Wahl M, Wax PM, McKay C. ACMT Position statement: alternative or contingency countermeasures for acetylcholinesterase inhibiting agents. J Med Toxicol. 2018;14(3):261\u20133.","journal-title":"J Med Toxicol"},{"issue":"3","key":"873_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.55460\/DQ96-STYU","volume":"17","author":"CJ Calvano","year":"2017","unstructured":"Calvano CJ, Enzenauer RW, Eisnor DE, Mazzoli RA. Atropine eye drops: a proposed field expedient substitute in the absence of atropine autoinjectors. J Spec Oper Med. 2017;17(3):81\u20133.","journal-title":"J Spec Oper Med"},{"key":"873_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1197\/j.aem.2006.10.099","volume":"14","author":"SM Bryant","year":"2007","unstructured":"Bryant SM, Rhee JW, Thompson TM, Aks SE. Pretreating rats with parenteral ophthalmic antimuscarinic agents decreases mortality from lethal organophosphate poisoning. Acad Emerg Med. 2007;14:370\u20132.","journal-title":"Acad Emerg Med."},{"key":"873_CR9","unstructured":"United States Food and Drug Administration. Atropine sulfate. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021146s015lbl.pdf . Accessed 7 Jul\u00a02021."},{"key":"873_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.schres.2016.10.039","volume":"182","author":"TE Matos Santana","year":"2017","unstructured":"Matos Santana TE, Capurso N, Ranganathan M, Yoon G. Sublingual atropine in the treatment of clozapine-induced sialorrhea. Schizophr Res. 2017;182:144\u20135.","journal-title":"Schizophr Res"},{"issue":"1","key":"873_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/ipd.12219","volume":"27","author":"J Norderyd","year":"2017","unstructured":"Norderyd J, Graf J, Marcusson A. Sublingual administration of atropine eyedrops in children with excessive drooling - a pilot study. Int J Paediatr Dent. 2017;27(1):22\u20139.","journal-title":"Int J Paediatr Dent"},{"issue":"7","key":"873_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/0269216306071702","volume":"20","author":"GG De Simone","year":"2006","unstructured":"De Simone GG, Ersenchlas JH, Junin M, Pereyra F, Brizuela R. Atropine drops for drooling: a randomized controlled trial. Palliat Med. 2006;20(7):665\u201371.","journal-title":"Palliat Med"},{"issue":"1","key":"873_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpainsymman.2012.01.006","volume":"45","author":"M Heisler","year":"2013","unstructured":"Heisler M, Hamilton G, Abbott A, Chengalaram A, Koceja T, Gerkin R. Randomized double-blind trial of sublingual atropine vs. placebo for the management of death rattle. J Pain Symptom Manage. 2013;45(1):14\u201322.","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"873_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1067\/moe.2001.111551","volume":"91","author":"S Pai","year":"2001","unstructured":"Pai S, Ghezzi EM, Ship JA. Development of a visual analogue scale questionnaire for subjective assessment of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2001;91(3):311\u20136.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"6","key":"873_CR15","first-page":"865","volume":"42","author":"M Eddleston","year":"2004","unstructured":"Eddleston M, Buckley NA, Checketts H, Senarathna L, Mohamed F, Sheriff MH, Dawson A. Speed of initial atropinisation in significant organophosphate pesticide poisoning. Clin Toxicol. 2004;42(6):865\u201375.","journal-title":"Clin Toxicol."},{"key":"873_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.etap.2008.10.007","volume":"27","author":"S Rajpal","year":"2009","unstructured":"Rajpal S, Mittal G, Sachdeva R, Chhillar M, Ali R, Agrawal SS, Kashyap R, Bhatnagar A. Development of atropine sulphate nasal drops and its pharmacokinetic safety evaluation in healthy human volunteers. Environ Toxicol Pharmacol. 2009;27:206\u201311.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"6","key":"873_CR17","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/mds.10276","volume":"17","author":"HC Hyson","year":"2002","unstructured":"Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17(6):1318\u201320.","journal-title":"Mov Disord"},{"key":"873_CR18","unstructured":"Meridian Medical Technologies, Inc., a Pfizer company. DUODOTE (atropine and pralidoxime chloride injection). https:\/\/www.meridianmeds.com\/sites\/default\/files\/duodote_uspi_2017.pdf . Accessed 5 Aug\u00a02021."}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-021-00873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-021-00873-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-021-00873-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T17:25:28Z","timestamp":1655227528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-021-00873-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1007\/s13181-021-00873-0","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"For Schwartz, Raulli, Laney, Coley, Walker, O\u2019Rourke, Raine, Horwith, Gao, Eisnor, Lu, Wolling: \u201cThe findings and conclusions in this article are those of the authors and do not necessarily represent the views of the US Department of Health and Human Services or its components. The information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the US Department of Health and Human Services. It does not represent and should not be construed to represent any agency determination or policy.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}